Last updated July 18, 2026
Key finding
HbA1c decreased by 1.0% at 6 months (P < 0.001).
This study investigated endovascular denervation targeting the celiac and hepatic arteries in patients with poorly controlled type 2 diabetes, finding significant reductions in HbA1c levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated endovascular denervation targeting the celiac and hepatic arteries in patients with poorly controlled type 2 diabetes, finding significant reductions in HbA1c levels.
This research highlights a potential new approach for managing type 2 diabetes, particularly in patients who struggle to control their blood sugar levels. By targeting specific arteries, this method may offer an alternative to traditional treatments, potentially improving patient outcomes and quality of life.
Non-randomized study design limits causal inferences. Sample size may affect the generalizability of results. Follow-up duration may not capture long-term effects.
Published in
Publication details and source links for this paper.
Zhi W, Tao P, Weifu L, et al. Endovascular denervation targeting the celiac and hepatic arteries in patients with poorly controlled type 2 diabetes. Signal Transduction and Targeted Therapy. 2025;10:371. doi:10.1038/s41392-025-02459-6
HbA1c decreased by 1.0% at 1 month (P < 0.001).
HbA1c decreased by 1.2% at 3 months.
Time in range increased by 15.4% at 1 month.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Endovascular denervation (EDN) targeting the celiac and hepatic arteries and Adverse events incidence, Blood pressure reduction, Device- and/or procedure-related major adverse events (MAEs), and 2 more.
This study contributes evidence to
Primary intervention
Endovascular denervation (EDN) targeting the celiac and hepatic arteries
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
5
Evidence pairs
555
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Adverse events incidence
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Adverse events incidence
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Blood pressure reduction
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Blood pressure reduction
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Device- and/or procedure-related major adverse events (MAEs)
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Device- and/or procedure-related major adverse events (MAEs)
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → HbA1c
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → HbA1c
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Time in range
Endovascular denervation (EDN) targeting the celiac and hepatic arteries → Time in range
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Endovascular denervation (EDN) targeting the celiac and hepatic arteries and Adverse events incidence, Endovascular denervation (EDN) targeting the celiac and hepatic arteries and Blood Pressure.
This study contributes to the evidence on the following intervention-outcome relationships.
Procedures
Curated evidence collections and hubs this study is part of.
All studies measuring Adverse events incidence
Measures Adverse events incidence as a key outcome.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
All studies on Endovascular denervation (EDN) targeting the celiac and hepatic arteries
Contributes to Endovascular denervation (EDN) targeting the celiac and hepatic arteries evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Endovascular denervation (EDN) targeting the celiac and hepatic arteries appears to improve Blood pressure reduction.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Blood pressure reduction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Endovascular denervation (EDN) targeting the celiac and hepatic arteries appears to improve Device- and/or procedure-related major adverse events (MAEs).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Device- and/or procedure-related major adverse events (MAEs)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Endovascular denervation (EDN) targeting the celiac and hepatic arteries appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Endovascular denervation (EDN) targeting the celiac and hepatic arteries for Adverse events incidence.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Adverse events incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
